Degarelix

Author： Frampton James E.   Lyseng-Williamson Katherine A.  

Publisher： Adis International

ISSN： 0012-6667

Source： Drugs, Vol.69, Iss.14, 2009-10, pp. : 1967-1976

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Degarelix: a guide to its use in advanced prostate cancer

By  

Drugs & Therapy Perspectives, Vol. 26, Iss. 3, 2010-03 ,pp. : 6-8

Adis International

Access to resources Recommend Favorite

Degarelix: a guide to its use in advanced prostate cancer

By Lyseng-Williamson Katherine A.  

Drugs & Therapy Perspectives, Vol. 28, Iss. 5, 2012-05 ,pp. : 6-10

Adis International

Access to resources Recommend Favorite

Degarelix less costly than goserelin for prostate cancer

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 642, 2011-01 ,pp. : 4-4

Adis International

Access to resources Recommend Favorite

Population Pharmacokinetic Modeling of a Subcutaneous Depot for GnRH Antagonist Degarelix

By Tornøe Christoffer W.   Agersø Henrik   Nielsen Henrik A.   Madsen Henrik   Jonsson E. Niclas  

Pharmaceutical Research, Vol. 21, Iss. 4, 2004-04 ,pp. : 574-584

Springer Publishing Company

Access to resources Recommend Favorite

Pharmacokinetic/Pharmacodynamic Modellingof GnRH Antagonist Degarelix: A Comparisonof the Non-linear Mixed-Effects Programs NONMEM and NLME

By Tornøe Christoffer   Agersø Henrik   Nielsen Henrik   Madsen Henrik   Jonsson E.  

Journal of Pharmacokinetics and Pharmacodynamics, Vol. 31, Iss. 6, 2004-12 ,pp. : 441-461

Springer Publishing Company

Access to resources Recommend Favorite